Reactions Weekly

, Volume 1761, Issue 1, pp 45–45 | Cite as

Anaplastic lymphoma kinase inhibitors

Development of drug resistance: case report
Case report


  1. Coleman N, et al. Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung Cancer 134: 117-120, Aug 2019. Available from: URL: - United Kingdom

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations